Clinical Trials Directory

Trials / Unknown

UnknownNCT03727828

Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure

Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure: DRAGON-HF Study

Status
Unknown
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
Shanghai 10th People's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The objective of this work is to investigate and then to sequence new biomarkers in the blood of patients with heart failure, and study their diagnostic, risk stratification and prognostic value.

Detailed description

Blood samples (plasma or serum) for heart failure patients presenting dyspnea or edema and with increased NT-proBNP. The objective of this work is to investigate and then to sequence new proteins or microRNAs in the blood of these patients for diagnostic, risk stratification and prognostic purpose.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPatients with heart failureParticipants will have serial blood collection on medical therapy for heart failure

Timeline

Start date
2018-11-15
Primary completion
2020-12-01
Completion
2021-02-28
First posted
2018-11-01
Last updated
2020-01-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03727828. Inclusion in this directory is not an endorsement.

Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure (NCT03727828) · Clinical Trials Directory